Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: Possible involvement of accelerated polyol pathway in its pathogenesis

Diabetes Research and Clinical Practice

Volumn 82, Issue 1, 2008, Pages 119-126

  Takizawa, Makoto ^a   Suzuki, Kiyoshi ^a,b   Matsubayashi, Tadashi ^a   Kikuyama, Munetsugu ^a,b   Suzuki, Haruhiko ^a   Takahashi, Kazuto ^a   Katsuta, Hidenori ^a   Mitsuhashi, Junko ^a   Nishida, Susumu ^a   Yamaguchi, Shinya ^a   Yoshimoto, Katsuhiko ^a   Itagaki, Eiji ^a   Ishida, Hitoshi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIMADA MUNICIPAL HOSPITAL   (Japan)

Author keywords

Bone resorption; Diabetic osteopenia; Osteoblasts; Osteoclasts; Polyol pathway

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALDOSE REDUCTASE INHIBITOR; CALCIUM; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MAGNESIUM; ORAL ANTIDIABETIC AGENT; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; POLYOL; SORBITOL;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; RISK FACTOR; URINARY EXCRETION;

ACID PHOSPHATASE; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; DIABETES MELLITUS, TYPE 2; HUMANS; ISOENZYMES; L-IDITOL 2-DEHYDROGENASE; MALE; MIDDLE AGED; OSTEOCALCIN; POLYMERS; SIGNAL TRANSDUCTION; SORBITOL;

EID: 52949150413     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.07.008     Document Type: Article

References (40)

1. Seino Y., and Ishida H. Diabetic osteopenia: pathophysiology and clinical aspects. Diabetes Metab. Rev. 11 (1995) 21-35
2. Piepkorn B., Kann P., Forst T., Andreas J., Pfützner A., and Beyer J. Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29 (1997) 584-591
3. Levin M.E., Boisseau V.C., and Avioli L.V. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med. 294 (1976) 241-245
4. Ishida H., Seino Y., Matsukura S., Ikeda M., Yawata M., Yamashita G., et al. Diabetic osteopenia and circulating levels of vitamin D metabolites in type 2 (noninsulin-dependent) diabetes. Metabolism 34 (1985) 797-801
5. Gertner J.M., Tamborlane W.V., Horst R.L., Sherwin R.S., Felig P., and Genel M. Mineral metabolism in diabetes mellitus: changes accompanying treatment with a portable subcutaneous insulin infusion system. J. Clin. Endocrinol. Metab. 50 (1980) 862-866
6. McNair P., Christensen M.S., Madsbad S., Christiansen C., and Transbøl I. Hypoparathyroidism in diabetes mellitus. Acta Endocrinol. (Copenh.) 96 (1981) 81-86
7. Ishida H., Suzuki K., Someya Y., Nishimura M., Sugimoto C., Goto M., et al. Possible compensatory role of parathyroid hormone-related peptide on maintenance of calcium homeostasis in patients with non-insulin-dependent diabetes mellitus. Acta Endocrinol. (Copenh.) 129 (1993) 519-524
8. Suzuki K., Sugimoto C., Takizawa M., Ishizuka S., Kikuyama M., Togawa H., et al. Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res. Clin. Pract. 48 (2000) 185-191
9. Frazer T.E., White N.H., Hough S., Santiago J.V., McGee B.R., Bryce G., et al. Alterations in circulating vitamin D metabolites in the young insulin-dependent diabetic. J. Clin. Endocrinol. Metab. 53 (1981) 1154-1159
10. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
11. Hakeda Y., Kobayashi Y., Yamaguchi K., Yasuda H., Tsuda E., Higashio K., et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem. Biophys. Res. Commun. 251 (1998) 796-801
12. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3597-3602
13. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 3540-3545
14. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprogerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
15. Epstein S. Bone-derived proteins. Trends Endocr. Metab. September/October (1989) 9-14
16. Ishida H., Seino Y., Taminato T., Usami M., Takeshita N., Seino Y., et al. Circulating levels and bone contents of bone gamma-carboxyglutamic acid-containing protein are decreased in streptozotocin-induced diabetes. Possible marker for diabetic osteopenia. Diabetes 37 (1988) 702-706
17. Verhaeghe J., Suiker A.M.H., Nyomba B.L., Visser W.J., Einhorn T.A., Dequeker J., et al. Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover and decreased osteocalcin synthesis. Endocrinology 124 (1989) 573-582
18. Ishida H., Seino Y., Takeshita N., Kurose T., Tsuji K., Okamoto Y., et al. Effect of pancreas transplantation on decreased levels of circulating bone gamma-carboxyglutamic acid-containing protein and osteopenia in rats with streptozotocin-induced diabetes. Acta Endocrinol. (Copenh.) 127 (1992) 81-85
19. Takeshita N., Ishida H., Yamamoto T., Koh G., Kurose T., Tsuji K., et al. Circulating levels and bone contents of bone gamma-carboxyglutamic acid-containing protein in rat models of non-insulin-dependent diabetes mellitus. Acta Endocrinol. (Copenh.) 128 (1993) 69-73
20. Suzuki K., Ishida H., Takeshita N., Taguchi Y., Sugimoto C., Nosaka K., et al. Circulating levels of tartrate-resident acid phosphatase in rat models of non-insulin-dependent diabetes mellitus. J. Diabetes Complications 12 (1998) 176-180
21. Okazaki R., Totsuka Y., Hamano K., Ajima M., Miura M., Hirota Y., et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J. Clin. Endrocrinol. Metab. 82 (1997) 2915-2920
22. Suzuki K., Kurose T., Takizawa M., Maruyama M., Ushikawa K., Kikuyama M., et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclatogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral. Diabetes Res. Clin. Pract. 68 (2005) 117-125
23. Williams J.P., Blair H.C., McDonald J.M., McKenna M.A., Jordan S.E., Williford J., et al. Regulation of osteoclastic bone resorption by glucose. Biochem. Biophys. Res. Commun. 235 (1997) 646-651
24. Nakano I., Tsugawa T., Shinohara R., Watanabe F., Fujita T., Nagata M., et al. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state. J. Diabetes Complications 17 (2003) 337-342
25. Pacifici R. Is there a causal role of IL-1 in postmenopausal bone loss?. Calcif. Tissue Int. 50 (1992) 295-299
26. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045
27. Hosoda K., Eguchi H., Nakamoto T., Kubota T., Honda H., Jindai S., et al. Sandwich immunoassay for intact human osteocalcin. Clin. Chem. 38 (1992) 2233-2238
28. Lau K.H., Onishi T., Wergedal J.E., Singer F.R., and Baylink D.J. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin. Chem. 33 (1987) 458-462
29. Fraser W.D., Durham B.H., Berry J.L., and Mawer E.B. Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labeled vitamin D tracer. Ann. Clin. Biochem. 34 (1997) 632-637
30. Melkko J., Niemi S., and Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36 (1990) 1328-1332
31. Donde M., Fledelius C., Qvist P., and Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin. Chem. 42 (1996) 1639-1644
32. Da Hanson M.A., Weis A.M., Bollen S.L., Maslan F.R., and Singer D.R. Specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptide in urine. J. Bone Miner. Res. 7 (1992) 1251-1258
33. Matsumoto C., Kushida K., Yamazaki K., Imose K., and Inoue T. Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif. Tissue Int. 55 (1994) 324-329
34. Price P.A., Parthemore J.G., and Deftos L.J. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone gla protein in the plasma of normal subjects and patients with bone disease. J. Clin. Invest. 66 (1980) 878-883
35. 3-induced effect on human osteoblastic-like MG-63 cells. J. Bone Miner. Res. 10 (1995) 1050-1056
36. Mercer N., Ahmed H., McCarthy A.D., Etcheverry S.B., Vasta G.R., and Cortizo A.M. AGE-R3/galectin-3 expression in osteoblast-like cells: regulation by AGEs. Mol. Cell. Biochem. 266 (2004) 17-24
37. Cortizo A.M., Lettieri M.G., Barrio D.A., Mercer N., Etcheverry S.B., and McCarthy A.D. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol. Cell. Biochem. 250 (2003) 1-10
38. Takagi M., Kasayama S., Yamamoto T., Motomura T., Hashimoto K., Yamamoto H., et al. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J. Bone Miner. Res. 12 (1997) 439-446
39. Schwartz A.V., Sellmeyer D.E., Ensrud K.E., Cauley J.A., Tabor H.K., Schreiner P.J., et al. Older women with diabetes have an increased risk of fracture: a prospective study. J. Clin. Endocrinol. Metab. 86 (2001) 32-38
40. Forsén L., Meyer H.E., Midthjell K., and Edna T.H. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag health survey. Diabetologia 42 (1999) 920-925